Shelter Pharma (543963) Q4 24/25 earnings summary

Executive summary

• Audited standalone financial results for the half year and year ended March 31, 2025, were approved by the Board on May 29, 2025, with an unmodified audit opinion.

• Internal and secretarial auditors were appointed for FY 2025-26 and for a five-year term, respectively.

Financial highlights

• Revenue from operations for FY 2025 was ₹5,066.02 lakh, up from ₹4,002.29 lakh in FY 2024.

• Net profit for FY 2025 was ₹723.74 lakh, compared to ₹620.02 lakh in FY 2024.

• EPS for FY 2025 was ₹6.26, up from ₹5.36 in FY 2024.

• Total equity and liabilities as of March 31, 2025, stood at ₹4,833.55 lakh, up from ₹3,791.48 lakh a year earlier.

• Cash and cash equivalents at year-end were ₹341.99 lakh, down from ₹503.98 lakh at the previous year-end.

Outlook and guidance

• The company continues to operate as a going concern, with no material uncertainties identified by auditors.